81 related articles for article (PubMed ID: 19345417)
1. The ambiguous role of interferon regulatory factor-1 (IRF-1) immunoexpression in myelodysplastic syndrome.
Pinheiro RF; Metze K; Silva MR; Chauffaille Mde L
Leuk Res; 2009 Oct; 33(10):1308-12. PubMed ID: 19345417
[TBL] [Abstract][Full Text] [Related]
2. Good and bad IRF-1: role in tumor suppression versus autoimmune disease.
Liebermann DA; Hoffman B
Leuk Res; 2009 Oct; 33(10):1301-2. PubMed ID: 19439353
[No Abstract] [Full Text] [Related]
3. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression.
Giannouli S; Tzoanopoulos D; Ritis K; Kartalis G; Moutsopoulos HM; Voulgarelis M
Ann Rheum Dis; 2004 May; 63(5):578-82. PubMed ID: 15082491
[TBL] [Abstract][Full Text] [Related]
4. Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells.
Maratheftis CI; Bolaraki PE; Giannouli S; Kapsogeorgou EK; Moutsopoulos HM; Voulgarelis M
Leuk Res; 2006 Sep; 30(9):1177-86. PubMed ID: 16483648
[TBL] [Abstract][Full Text] [Related]
5. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
[TBL] [Abstract][Full Text] [Related]
6. The 5q- syndrome and autoimmune phenomena: report of three cases.
Pinheiro RF; Silva MR; Chauffaille Mde L
Leuk Res; 2006 Apr; 30(4):507-10. PubMed ID: 16219353
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study.
Giannouli S; Voulgarelis M; Zintzaras E; Tzioufas AG; Moutsopoulos HM
Rheumatology (Oxford); 2004 May; 43(5):626-32. PubMed ID: 14983106
[TBL] [Abstract][Full Text] [Related]
8. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
9. Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia.
Neumann F; Gattermann N; Barthelmes HU; Haas R; Germing U
Leuk Res; 2009 Feb; 33(2):232-6. PubMed ID: 18639338
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.
Voulgarelis M; Giannouli S; Ritis K; Tzioufas AG
Eur J Clin Invest; 2004 Oct; 34(10):690-700. PubMed ID: 15473894
[TBL] [Abstract][Full Text] [Related]
11. [The myelodysplastic syndrome and autoimmunity].
Laursen SB; Nielsen MØ; Hasselbalch HC
Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.
Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E
J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024
[TBL] [Abstract][Full Text] [Related]
13. Expression of interferon regulatory factor 1, 3, and 7 in primary Sjögren syndrome.
Zheng L; Yu C; Zhang Z; Yang C; Cai X
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May; 107(5):661-8. PubMed ID: 19426920
[TBL] [Abstract][Full Text] [Related]
14. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients.
Li L; Liu XP; Nie L; Yu MH; Zhang Y; Qin TJ; Xiao ZJ
Leuk Res; 2009 Sep; 33(9):1194-8. PubMed ID: 19128829
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.
Cesana C; Klersy C; Brando B; Nosari A; Scarpati B; Scampini L; Molteni A; Nador G; Santoleri L; Formenti M; Valentini M; Mazzone A; Morra E; Cairoli R
Leuk Res; 2008 Nov; 32(11):1715-23. PubMed ID: 18456323
[TBL] [Abstract][Full Text] [Related]
16. Increase of IRF-1 gene expression and impairment of T regulatory cells suppression activity on patients with myelodysplastic syndrome: A longitudinal one-year study.
Perazzio AS; Oliveira JS; Figueiredo VL; Chauffaille ML
Leuk Res; 2017 Apr; 55():6-17. PubMed ID: 28113084
[TBL] [Abstract][Full Text] [Related]
17. The relationship between myelodysplastic syndromes and autoimmune disorders.
Zhao S; Mao H; Wang H; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):311-3. PubMed ID: 12411063
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group.
Galanopoulos AG; Symeonidis A; Kourakli A; Papadaki EA; Tsaftaridis P; Terpos E; Aktipi A; Roussou P; Protopappa M; Pappaioannou M; Zikos P; Speletas M; Parcharidou A; Laoutaris N; Anagnostopoulos NI; Meletis J; Pangalis GA; Zoumbos N; Viniou N;
Eur J Haematol; 2007 Jan; 78(1):89-90. PubMed ID: 17302860
[No Abstract] [Full Text] [Related]
19. Interferon regulatory factor-1 myelodysplasia and leukemia.
Liebermann DA; Hoffman B
Leuk Res; 2006 Sep; 30(9):1069-71. PubMed ID: 16620966
[No Abstract] [Full Text] [Related]
20. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared to -7/del(7q) MDS.
Slovak ML; O'Donnell M; Smith DD; Gaal K
Cancer Genet Cytogenet; 2009 Sep; 193(2):78-85. PubMed ID: 19665067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
